<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0120-0011</journal-id>
<journal-title><![CDATA[Revista de la Facultad de Medicina]]></journal-title>
<abbrev-journal-title><![CDATA[rev.fac.med.]]></abbrev-journal-title>
<issn>0120-0011</issn>
<publisher>
<publisher-name><![CDATA[Universidad Nacional de Colombia]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0120-00112016000400679</article-id>
<article-id pub-id-type="doi">10.15446/revfacmed.v64n4.53574</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Evaluación de las prescripciones autorizadas entre 2010 y 2011 por vía judicial en Bogotá, D.C., Colombia]]></article-title>
<article-title xml:lang="en"><![CDATA[Evaluation of prescriptions authorized between 2010 and 2011 through judicial protection in Bogotá]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Portilla-Pinzón]]></surname>
<given-names><![CDATA[Alfredo]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[López]]></surname>
<given-names><![CDATA[José Julián]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Montoya-Cañon]]></surname>
<given-names><![CDATA[Mauricio]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Machado-Alba]]></surname>
<given-names><![CDATA[Jorge Enrique]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Universidad Nacional de Colombia Facultad de Ciencias Departamento de Farmacia]]></institution>
<addr-line><![CDATA[Bogotá D.C]]></addr-line>
<country>Colombia</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Universidad Tecnológica de Pereira Audifarma S.A ]]></institution>
<addr-line><![CDATA[Pereira ]]></addr-line>
<country>Colombia</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>12</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>12</month>
<year>2016</year>
</pub-date>
<volume>64</volume>
<numero>4</numero>
<fpage>679</fpage>
<lpage>685</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_arttext&amp;pid=S0120-00112016000400679&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_abstract&amp;pid=S0120-00112016000400679&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_pdf&amp;pid=S0120-00112016000400679&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen  Introducción. La tutela es una herramienta legal empleada para garantizar el derecho a la salud en Colombia.  Objetivo. Evaluar la racionalidad terapéutica de prescripciones de medicamentos autorizadas por tutela en pacientes afiliados al Sistema General de Seguridad Social en Salud.  Materiales y métodos. Estudio descriptivo con recolección retrospectiva de información de bases de datos e historias clínicas de pacientes con medicamentos ordenados por acción judicial para tres aseguradoras en Bogotá, D.C. durante los años 2010 y 2011. Se consideraron la indicación, los consumos, las dosis, la duplicidad terapéutica, el riesgo de interacciones y los costos.  Resultados. Se obtuvo información de 3 469 pacientes que solicitaron 2 419 medicamentos por tutela, siendo los más comunes antiepilépticos (10.7%), vitaminas (10%), hipoleipemiantes (5%)y antidiabéticos (4.8%). En el 75.5% de los casos el medicamento se correlacionó con el diagnóstico y el 66% de los pacientes estuvo expuesto a riesgos de interacciones farmacológicas. Se observó mayor duplicidad terapéutica en antiinflamatorios no esteroideos y antihipertensivos. El costo promedio de cada dispensación por tutela se estimó en COP 453 221 (USD 236.5).  Conclusiones. Se evidencian problemas de racionalidad terapéutica en medicamentos ordenados por tutela, lo cual puede implicar mayores riesgos para la salud de los pacientes. Es recomendable un asesoramiento científico más riguroso con la finalidad de evitar posibles riesgos de interacciones y duplicidades terapéuticas.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract  Introduction: Judicial protection (tutela in Spanish) is a legal tool used to ensure the right to health in Colombia.  Objective: To evaluate the therapeutic rationale of drug prescriptions authorized through judicial protection for patients enrolled in the General Social Security Health System.  Materials and methods: Descriptive study with retrospective collection of information from databases and patient records associated with medications ordered by court action against three health insurers in Bogotá, D.C., during 2010 and 2011. Prescription, consumption, doses, therapeutic duplication, risk of interactions and costs were considered.  Results: Information of 3 469 patients who requested 2 419 prescribed drugs through judicial protection was obtained; the most common drugs were anticonvulsants (10.7%), vitamins (10%), lipid-lowering medications (5%) and anti-diabetic drugs (4.8%). In 75.5% of cases the drug was correlated with the diagnosis and 66% of patients were exposed to drug interaction risks. Greater therapeutic duplication was observed in non-steroidal anti-inflammatory and antihypertensive drugs. The average cost of each dispensation per judicial protection issued was estimated at COP 453 221 (USD 236.5).  Conclusions: Therapeutic rationality issues are evident in prescription drugs ordered by judicial protection, which may involve greater risks to the health of patients. A more rigorous scientific advice is recommended in order to avoid possible interactions and therapeutic duplications.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Farmacoepidemiología]]></kwd>
<kwd lng="es"><![CDATA[Interacciones de drogas]]></kwd>
<kwd lng="es"><![CDATA[Utilización de medicamentos]]></kwd>
<kwd lng="es"><![CDATA[Prescripciones de medicamentos]]></kwd>
<kwd lng="es"><![CDATA[Colombia (DeCS).]]></kwd>
<kwd lng="en"><![CDATA[Pharmacoepidemiology]]></kwd>
<kwd lng="en"><![CDATA[Drug Interactions]]></kwd>
<kwd lng="en"><![CDATA[Drug Utilization]]></kwd>
<kwd lng="en"><![CDATA[Drug Prescriptions]]></kwd>
<kwd lng="en"><![CDATA[Colombia (MeSH).]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<nlm-citation citation-type="book">
<collab>Colombia. Asamblea Nacional Constituyente</collab>
<source><![CDATA[Constitución Política de Colombia de 1991]]></source>
<year>1991</year>
<publisher-loc><![CDATA[Bogotá, D.C. ]]></publisher-loc>
<publisher-name><![CDATA[Gaceta Constitucional 116]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B2">
<nlm-citation citation-type="book">
<collab>Defensoría del Pueblo</collab>
<source><![CDATA[La tutela y derecho a la Salud 2012]]></source>
<year>2013</year>
<publisher-loc><![CDATA[Bogotá, D.C. ]]></publisher-loc>
<publisher-name><![CDATA[Defensoría del Pueblo]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B3">
<nlm-citation citation-type="book">
<collab>Organización Mundial de la Salud</collab>
<source><![CDATA[Promoción del uso racional de medicamentos: componentes centrales]]></source>
<year>2002</year>
<publisher-loc><![CDATA[Ginebra ]]></publisher-loc>
<publisher-name><![CDATA[Perspectivas Políticas de la OMS sobre Medicamentos No. 5]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B4">
<nlm-citation citation-type="book">
<collab>Consejo Nacional de Política Económica y Social, Departamento Nacional de Planeación</collab>
<source><![CDATA[Documento Conpes Social: Política Farmacéutica Nacional]]></source>
<year>2012</year>
<publisher-loc><![CDATA[Bogotá, D.C. ]]></publisher-loc>
<publisher-name><![CDATA[MinSalud]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B5">
<nlm-citation citation-type="book">
<collab>Defensoría del Pueblo</collab>
<source><![CDATA[La tutela y derecho a la Salud 2010]]></source>
<year>2011</year>
<publisher-loc><![CDATA[Bogotá, D.C. ]]></publisher-loc>
<publisher-name><![CDATA[Defensoría del Pueblo]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B6">
<nlm-citation citation-type="">
<collab>Colombia. Corte Constitucional</collab>
<source><![CDATA[Sentencia T-760 de 2008 (julio 31). M.P. Manuel José Cepeda Espinosa]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B7">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Farmacoepidemiología. Estudios de Utilización de Medicamentos. Parte I: Concepto y metodología]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Álvarez-Luna]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<source><![CDATA[Seguim Farmacoter]]></source>
<year>2004</year>
<volume>2</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>129-36</page-range></nlm-citation>
</ref>
<ref id="B8">
<nlm-citation citation-type="">
<collab>Drug Approvals and Databases</collab>
<source><![CDATA[Silver Spring: U.S. Food and Drug Administration (FDA)]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B9">
<nlm-citation citation-type="book">
<source><![CDATA[Definition and general considerations]]></source>
<year></year>
<publisher-loc><![CDATA[Olso ]]></publisher-loc>
<publisher-name><![CDATA[World Health Organization Collaboration Centre for Drug Statistics Methodology]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B10">
<nlm-citation citation-type="">
<collab>Micromedex® Solutions</collab>
<source><![CDATA[Web application access. Truven Health Analytics Inc]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B11">
<nlm-citation citation-type="book">
<collab>WHO Collaboration Centre for Drug Statistics Methodology</collab>
<source><![CDATA[ATC/DDD Index 2014]]></source>
<year>2014</year>
<publisher-loc><![CDATA[Oslo ]]></publisher-loc>
<publisher-name><![CDATA[WHO]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B12">
<nlm-citation citation-type="book">
<collab>Colombia. Comisión de Regulación en Salud</collab>
<source><![CDATA[Acuerdo 29 de 2011 (diciembre 28): Por el cual se sustituye el Acuerdo 28 de 2011 que define, aclara y actualiza integralmente el Plan Obligatorio de Salud]]></source>
<year>2011</year>
<publisher-loc><![CDATA[Bogotá, D.C. ]]></publisher-loc>
<publisher-name><![CDATA[Diario Oficial 48298]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B13">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Definición de medicamento genérico ¿un fin o un medio? Análisis de la regulación en 14 países de la Región de las Américas]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Vacca-González]]></surname>
<given-names><![CDATA[CP]]></given-names>
</name>
<name>
<surname><![CDATA[Fitzgerald]]></surname>
<given-names><![CDATA[JF]]></given-names>
</name>
<name>
<surname><![CDATA[Bermúdez]]></surname>
<given-names><![CDATA[JAZ]]></given-names>
</name>
</person-group>
<source><![CDATA[Rev. Panam. Salud Publica]]></source>
<year>2006</year>
<volume>20</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>314-23</page-range></nlm-citation>
</ref>
<ref id="B14">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Generic statins: effectiveness, affordability, and patient adherence]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cullen]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Murray]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Harnett]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<source><![CDATA[Ann. Intern. Med]]></source>
<year>2014</year>
<volume>161</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>447-8</page-range></nlm-citation>
</ref>
<ref id="B15">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Policies to promote use of generic medicines in low and middle income countries: a review of published literature, 2000-2010]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kaplan]]></surname>
<given-names><![CDATA[WA]]></given-names>
</name>
<name>
<surname><![CDATA[Ritz]]></surname>
<given-names><![CDATA[LS]]></given-names>
</name>
<name>
<surname><![CDATA[Vitello]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Wirtz]]></surname>
<given-names><![CDATA[VJ]]></given-names>
</name>
</person-group>
<source><![CDATA[Health Policy]]></source>
<year>2012</year>
<volume>106</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>211-24</page-range></nlm-citation>
</ref>
<ref id="B16">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Factors influencing consumer purchasing patterns of generic versus brand name over-the-counter drugs]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kohli]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Buller]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<source><![CDATA[South Med. J]]></source>
<year>2013</year>
<volume>106</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>155-60</page-range></nlm-citation>
</ref>
<ref id="B17">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Analysis of drug interactions at the end of life]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Morgan]]></surname>
<given-names><![CDATA[NA]]></given-names>
</name>
<name>
<surname><![CDATA[Rowett]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Currow]]></surname>
<given-names><![CDATA[DC]]></given-names>
</name>
</person-group>
<source><![CDATA[BMJ Support Palliat. Care]]></source>
<year>2015</year>
<volume>5</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>281- 6</page-range></nlm-citation>
</ref>
<ref id="B18">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Efectividad y seguridad del esquema genérico lamivudina/zidovudina/efavirenz en pacientes VIH (+). Estudio fase IV y comparación con el mismo esquema de medicamentos innovadores]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gutiérrez]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Amariles]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Galindo]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Mueses]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Agudelo]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Hincapié]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<source><![CDATA[Vitae]]></source>
<year>2013</year>
<volume>20</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>30-40</page-range></nlm-citation>
</ref>
<ref id="B19">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Estudio de bioequivalencia de montelukast en tabletas masticables de 5 mg]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Medina]]></surname>
<given-names><![CDATA[AP]]></given-names>
</name>
<name>
<surname><![CDATA[Olaya]]></surname>
<given-names><![CDATA[FJ]]></given-names>
</name>
<name>
<surname><![CDATA[Navas]]></surname>
<given-names><![CDATA[MP]]></given-names>
</name>
<name>
<surname><![CDATA[Tilano]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
<name>
<surname><![CDATA[Muñoz]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<source><![CDATA[Biomedica]]></source>
<year>2012</year>
<volume>32</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>399-407</page-range></nlm-citation>
</ref>
<ref id="B20">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Off-patent generic medicines vs. off-patent brand medicines for six reference drugs: a retrospective claims data study from five local healthcare units in the Lombardy Region of Italy]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Colombo]]></surname>
<given-names><![CDATA[GL]]></given-names>
</name>
<name>
<surname><![CDATA[Agabiti-Rosei]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Margonato]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Mencacci]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Montecucco]]></surname>
<given-names><![CDATA[CM]]></given-names>
</name>
<name>
<surname><![CDATA[Trevisan]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<source><![CDATA[PLoS One]]></source>
<year>2013</year>
<volume>8</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>e82990</page-range></nlm-citation>
</ref>
<ref id="B21">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Generic medications for you, but brand-name medications for me]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Keenum]]></surname>
<given-names><![CDATA[AJ]]></given-names>
</name>
<name>
<surname><![CDATA[Devoe]]></surname>
<given-names><![CDATA[JE]]></given-names>
</name>
<name>
<surname><![CDATA[Chisolm]]></surname>
<given-names><![CDATA[DJ]]></given-names>
</name>
<name>
<surname><![CDATA[Wallace]]></surname>
<given-names><![CDATA[LS]]></given-names>
</name>
</person-group>
<source><![CDATA[Res. Social Adm. Pharm]]></source>
<year>2012</year>
<volume>8</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>574-8</page-range></nlm-citation>
</ref>
<ref id="B22">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[State laws regulating prescribing of controlled substances: balancing the public health problems of chronic pain and prescription painkiller abuse and overdose]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[García]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
</person-group>
<source><![CDATA[J. Law Med. Ethics]]></source>
<year>2013</year>
<volume>41</volume>
<numero>^sSuppl 1</numero>
<issue>^sSuppl 1</issue>
<supplement>Suppl 1</supplement>
<page-range>42-5</page-range></nlm-citation>
</ref>
<ref id="B23">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[[Prescribing information for drugs-legal and regulatory implications]]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Yahalom]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[Shani]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<source><![CDATA[Harefuah]]></source>
<year>2014</year>
<volume>153</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>671-4</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
